Cancer rarely comes to mind when most people think of vaccines, but that appears to be changing.
Immunotherapy is the future of cancer treatment.
Hundreds of entrepreneurs, company executives, investors, scientists, researchers, and policymakers gathered at the 20th Annual BioFlorida Conference to celebrate two decades of advancing Florida’s life sciences.
In an interview with CURE, Zamarin, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses immunotherapy for patients with ovarian cancer.
From chickenpox to influenza to pneumonia and more, vaccines are one of the most remarkable breakthroughs in medical history. What if your own genetic makeup could be used to harness immunization for one of the scariest pathogens—cancer?
Recent scientific advances and cutting-edge cancer therapies are giving an old idea new life.
IMFINZI™ (Durvalumab) Granted Breakthrough Therapy Designation by US FDA for Patients with Locally Advanced Unresectable Non-Small Cell Lung Cancer
AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for IMFINZI™ (durvalumab), an anti-PD-L1 monoclonal antibody, being investigated for the treatment of patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation therapy.
The FDA expanded the approved uses for an immunotherapy drug that has successfully treated certain lung cancers and melanoma.
AstraZeneca’s IMFINZI™ (Durvalumab) Receives US FDA Accelerated Approval For Previously Treated Patients With Advanced Bladder Cancer
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to IMFINZI™ (durvalumab). IMFINZI is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy, or whose disease has progressed within 12 months of receiving platinum-containing chemotherapy before (neoadjuvant) or after (adjuvant) surgery.